A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-25 and is reviewed periodically as new material appears.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport; not approved as medicine | Listed by WADA at all times. |
| Common synonyms | GW501516, GW-501516, endurobol | Cardarine is a colloquial name. |
| Typical analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Common test matrix | Urine | Blood and dried blood spots also possible. |
| Legal classification | Varies by country | Often treated as unapproved drug or research chemical. |
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
In Japan, the installation of a rotary engine gave Japanese buyers a financial advantage when it came time to pay the annual road tax in that they bought a car that was more powerful than a traditional inline engine, but without having the penalty for having an engine in the higher 1.0-litre tax bracket. This was the only generation of the Familia that had the rotary engine offered. When Mazda updated the rotary engine to single distributor design in late 1973 with a raft of improvements to improve reliability and fuel economy, the smaller 10A engine was discontinued. Upgrading the Familia Rotary to the 12A engine would have cost the car its tax advantage in Japan, and the decision to discontinue it was made, despite the Familia body continuing production for some years to follow. The R100 was one of the first Mazda cars imported into the United States for the new Mazda Motors of America, sold in model years 1971 and 1972. Due to US regulations it was released in North America with round headlights fitted in place of the rectangular lights fitted in all other markets. It was a surprising hit with the American public, though sales were limited to some Northwestern states initially. Following on the success of the Cosmo Sports at Nürburgring in 1968, Mazda decided to race another rotary car. The Familia Rotary coupé won its first outing, at the Grand Prix of Singapore, in April 1969. Next, the company took on the touring car endurance challenge at Spa, the Spa 24 Hours. For 1969, Mazda entered a pair of Familia Rotary coupés.
Kennedy (1919–2011), American biochemist at the Harvard Medical School known for work on lipid metabolism and membrane function. Dorothee Kern (born 1966), Biochemist at Brandeis University known for work on the motion of proteins using genomic data.
=== Bag of cement and bag mix === The mass of an old bag of cement was one hundredweight (112 pounds, 51 kg). In the concrete and petroleum industry, however, a bag of cement is defined as 94 lb (43 kg) because it has an apparent volume close to 1 cubic foot (28 litres).
Sources: en.wikipedia.org
To assess the location and severity of a nerve injury, clinical assessment is commonly combined with electrodiagnostic tests. Injuries to the myelin are usually the least severe (neuropraxia), while injuries to the axons and supporting structures are more severe (axonotmesis is moderate injury, while neurotmesis is severe injury). It may be difficult to differentiate the severity by clinical findings due to common neurological impairments, including motor and sensory impairments distal to the lesion.
Kumārajīva is known to have travelled repeatedly between Kucha and Kashmir around this time, and he may have been instrumental, among many others, in the transmission of this art. The structural prototype of the cave may be Kara Tepe in Bactria. The flat, well-delineated surfaces of the paintings remind of the Roman Opus sectile technique, which prospered circa 331–359 CE.
In nuclear physics, secular equilibrium is a situation in which the quantity of a radioactive isotope remains constant because its production rate (e.g., due to decay of a parent isotope) is equal to its decay rate. An example of this is the germanium-68/gallium-68 generator commonly used for the preparation of gallium-68 radiopharmaceuticals for PET imaging.
Sources: en.wikipedia.org
== Etymology of anesthesia == In ancient Greek texts, such as the Hippocratic Corpus and the dialogue Timaeus, the term ἀναισθησία (anaisthēsíā) is used, which translates to "without sensation". This term is derived from the prefix ἀν- (an-), meaning "without", and αἴσθησις (aisthēsis), which means "sensation". The concept of anaisthēsia is significant in understanding the historical foundations of anesthesia and its relevance in medical practices. In 1679, Steven Blankaart published Lexicon medicum graeco-latinum with the Latin term anaisthesia. In 1684, an English translation appeared titled A Physical Dictionary, with anesthesia defined as a "defect of sensation, as in paralytic and blasted persons". Subsequently, the term and variant spellings like anæsthesia are used in medical literature signifying "insensibility". In 1846, in a letter, Oliver Wendell Holmes proposed the term anesthesia to be used for the state induced by an agent and anesthetic for the agent itself. Holmes motivates this with earlier uses of anesthesia in medical literature to mean "insensibility", particularly to "objects of touch".
==== Public figure ==== Throughout the fifties and sixties, Adorno became a public figure, not simply through his books and essays but also through his appearances in radio and newspapers. In talks, interviews, and round-table discussions broadcast on Hessen Radio, South-West Radio, and Radio Bremen, Adorno discussed topics as diverse as "The Administered World" (September 1950), "What is the Meaning of 'Working Through the Past?'" (February 1960), and "The Teaching Profession and its Taboos" (August 1965). Additionally, he frequently wrote for Frankfurter Allgemeine, Frankfurter Rundschau, and the weekly Die Zeit. At the invitation of Wolfgang Steinecke, Adorno took part in the Darmstadt Summer Courses for New Music in Kranichstein from 1951 to 1958. Yet conflicts between the so-called Darmstadt school, which included composers like Pierre Boulez, Karlheinz Stockhausen, Luigi Nono, Bruno Maderna, Karel Goeyvaerts, Luciano Berio, and Gottfried Michael Koenig, soon arose, receiving explicit expression in Adorno's 1954 lecture, "The Aging of the New Music," where he argued that atonality's freedom was being restricted to serialism in much the same way as it was once restricted by twelve-tone technique. With his friend Eduard Steuermann, Adorno feared that music was being sacrificed to stubborn rationalization. During this time, Adorno not only produced a significant series of notes on Beethoven (which was never completed and only published posthumously) but also published Mahler: A Musical Physiognomy in 1960.
It is likely bloodletting was an antecedent to acupuncture. According to historians Lu Gwei-djen and Joseph Needham, there is substantial evidence that acupuncture may have begun around 600 BC. Some hieroglyphs and pictographs from that era suggests acupuncture and moxibustion were practised. However, historians Lu and Needham said it was unlikely a needle could be made out of the materials available in China during this time period. It is possible that bronze was used for early acupuncture needles. Tin, copper, gold and silver are also possibilities, though they are considered less likely, or to have been used in fewer cases. If acupuncture was practised during the Shang dynasty (1766 to 1122 BC), organic materials like thorns, sharpened bones, or bamboo may have been used. Once methods for producing steel were discovered, it would replace all other materials, since it could be used to create a very fine, but sturdy needle. Lu and Needham noted that all the ancient materials that could have been used for acupuncture and which often produce archaeological evidence, such as sharpened bones, bamboo or stones, were also used for other purposes. An article in Rheumatology said that the absence of any mention of acupuncture in documents found in the tomb of Mawangdui from 198 BC suggest that acupuncture was not practised by that time.
=== Cold mixed absinthe === Many modern absinthes are produced using a cold-mix process. This inexpensive method of production does not involve distillation, and is regarded as inferior for the same reasons that give cause for cheaply compounded gin to be legally differentiated from distilled gin. The cold mixing process involves the simple blending of flavouring essences and artificial colouring in commercial alcohol, in similar fashion to most flavoured vodkas and inexpensive liqueurs and cordials. Some modern cold-mixed absinthes have been bottled at strengths approaching 90% ABV. Others are presented simply as a bottle of plain alcohol with a small amount of powdered herbs suspended within it. The lack of a formal legal definition in most countries to regulate the production and quality of absinthe has enabled cheaply made products to be falsely presented as traditional in production and composition. In Switzerland, the only country with a formal legal definition of absinthe, any absinthe product not obtained by maceration and distillation or coloured artificially cannot be sold as absinthe.
Sources: en.wikipedia.org
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.
Laboratories use liquid chromatography-tandem mass spectrometry to detect GW501516 and its metabolites. Urine is commonly tested, and testing can occur in and out of competition.
No, cardarine is not a SARM. It is a PPARδ agonist, which acts on a different receptor. The two classes are often confused in online discussions.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.